Sanofi deal strategy will shun hep C in global hunt for new 'pearls'

Imitation is the sincerest form of flattery. And Sanofi ($SNY) CEO Chris Viehbacher may have been paying Bristol-Myers Squibb ($BMY) a compliment when he described his acquisition strategy to Bloomberg as a "string of pearls" approach--borrowing language and a strategy that BMS has used to great effect over the last few years.

What Viehbacher won't be doing, though, is following in Bristol's footsteps in the frenzied hepatitis C field. Bristol, of course, just agreed to shell out $2.5 billion to buy Inhibitex ($INHX), highlighting the premiums that clinical-stage technologies in the field are fetching these days. Viehbacher is steering clear of hep C acquisitions, telling Bloomberg that Sanofi plans to use partnerships to beef up its early-stage research pipelines.

Sanofi is shopping for new pearls in the $2.6 billion-and-under market. And he'd like to do his buying as far from crowded bargaining tables as he can get.

"The trick in M&A is to go find something not everybody is looking at," Viehbacher tells the business news service.

- here's the story from Bloomberg

Suggested Articles

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.